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Abstract 
Context. 50% of pediatric low-grade gliomas affect the optic pathway, hypothalamus and 
suprasellar areas (OP/HSGs) resulting in significant long-term neuroendocrinopathy.  
Objective. To dissect tumor- from treatment-related risk factors for OP/HSG-associated 
neuroendocrinopathy. 
Design. Retrospective case notes analysis of 166 children with newly-diagnosed OP/HSGs 
at our quaternary center between 1980-2010 by multivariate Cox, linear and logistic 
regression. 
Results. Patients were of median (range) age 4.9 (0.2-15.4) years at diagnosis and followed 
up for 8.3 (0.04-26.8) years. Despite high 20-year overall survival (81.0%), progression-free 
and endocrine event-free (EEFS) survival were 47.2% and 20.8% respectively. EEFS 
declined up to 15 years post-diagnosis, with hypothalamic involvement (p<0.001) being 
implicated more than radiotherapy (p=0.008) in earlier endocrinopathy; the reverse being 
true of its density (radiotherapy p<0.001; hypothalamic involvement p=0.006). GH deficiency 
(GHD) was commonest (40.3%), followed by central precocious puberty (CPP, 26.0%), 
gonadotropin (GnD, 20.4%), TSH (13.3%), and ACTH (13.3%) deficiencies. GHD increased 
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with later treatment eras (p<0.01), but replacement did not increase progression. CPP was 
associated with future GnD (p<0.05). Posterior pituitary dysfunction (PPD, 7.2%) occurred in 
57.9% after only biopsies or shunt procedures, and was associated with 6/13 deaths. 50.2% 
became obese. Tumor extent, surgery and increased endocrinopathy, rather than 
radiotherapy, predicted visuo-cognitive morbidity. 
Conclusions. This first longitudinal OP/HSG-specific study demonstrates that hypothalamo-
pituitary dysfunction evolves hierarchically over decades. Tumor location predicts its speed 
of onset and radiotherapy its density. GnD can evolve from previous CPP, whilst life-
threatening PPD can occur after any surgery. Our data suggest that recent radiation-
avoiding chemotherapeutic strategies have increased GHD without improving survival. 
 
Keywords: Pediatric optic glioma, juvenile pilocytic astrocytoma, survivorship, endocrine 
morbidity, neurology 
 
Introduction 
Over 40% of central nervous system tumors are low-grade gliomas (LGGs).(1) Although 
classed as benign grade I or II astrocytic tumors (the majority being juvenile pilocytic 
astrocytomas),(2) they exhibit unpredictable growth with the possibility of spontaneous 
involution, late-onset progression, or leptomeningeal metastases.(3-5) 10-16% are 
associated with neurofibromatosis type 1 (NF-1), behaving more indolently and occurring 
more anteriorly, bilaterally and multifocally.(5-11) Although 50-60% of pediatric LGGs involve 
the cerebellum, cerebral hemispheres or brainstem, 30-50% affect the optic nerves, chiasm, 
tracts, hypothalamus and suprasellar midline, collectively referred to here as optic pathway, 
hypothalamic and suprasellar gliomas (OP/HSGs).(9, 11) 
 
The first international whole-brain LGG study (LGG1) showed that the highest overall- (OS) 
and progression-free survival (PFS) resulted from complete tumor resection.(10, 11) 
However, due to their proximity to vital hypothalamo-pituitary and visual structures, only 3% 
of OP/HSGs were resectable compared with 94% of cerebellar LGGs.(11) Despite high 
survival rates (86-100%)(8-13), survivors face significant endocrine, visual and 
neurocognitive morbidity. These deficits are multifactorial in origin, the relative patient-, 
tumor- and treatment-related contributions being unclear, although in clinical practice 
radiotherapy is frequently blamed.(9) 
 
The reported incidence of neuroendocrinopathies in survivors varies from 39-100%,(14, 15) 
with studies limited to small retrospective cohorts,(16, 17) being of short duration (<10 
years),(18, 19) focusing on radiotherapy-treated patients,(15, 20) or analyzing outcomes 
cross-sectionally, thereby not recognizing their temporal evolution.(9, 21) The only 
longitudinal report to date did not compare OP/HSG-specific outcomes with LGGs arising 
elsewhere in the central nervous system and omitted gonadotropin and posterior pituitary 
dysfunction (PPD) entirely.(9) Our aim was to determine risk factors for neuroendocrine 
dysfunction in our large single-center, 30-year OP/HSG-specific cohort by multivariate 
survival analysis, testing the a priori hypothesis: “the incidence and severity of 
neuroendocrine morbidity is independently predicted by tumor location and treatment 
strategy”. 
 
Methods 
Study cohort 
 
Great Ormond Street Hospital for Children (GOSH) is a quaternary pediatric neuro-oncology 
center for southeast England. A search on 5 March 2012 of our central tumor registry 
identified all children <16 years with newly-registered OP/HSGs between 1 January 1980 
and 31 December 2010. Cases were included if there was a biopsy-proven or radiologically-
diagnosed OP/HSG treated and followed-up at GOSH. LGGs affecting the basal ganglia, 
thalamus and third ventricle were included as their suprasellar midline locations might affect 
long-term neuroendocrine morbidity. Patients treated elsewhere or those whose radiological 
diagnoses were subsequently proven histologically erroneous were excluded. A 
retrospective case note, laboratory and radiology data review was performed. 
 
Definitions 
Independent variables 
 
Patient-related data on age at diagnosis (stratified as <1, 1-5, and >5 years),(11) sex, 
ethnicity, NF-1 status, the presence and duration of symptoms or diencephalic syndrome 
were collected, alongside tumor stage (as per the modified Dodge classification (MDC, 
Supplemental Table 1)),(7) hypothalamic involvement, and the presence of leptomeningeal 
metastases and hydrocephalus. Where tumors involved multiple regions, the highest (most 
posterior) MDC stage was recorded, whilst tumors outside MDC-defined regions (e.g. pure 
thalamic tumors) were coded as “other midline”. WHO histological tumor grade(2) was 
recorded where available.  
 
Treatment modalities were recorded as surgical resections (any tumor debulking, including 
biopsies), decompression procedures (aimed at relieving raised intracranial pressure, e.g. 
cyst aspirations and shunt procedures), radiotherapy or chemotherapy, and were classified 
as being part of the initial (primary) or cumulative (final) treatment strategy. Focal 
radiotherapy was delivered to total doses of 48-55 Gy in 25-30 fractions. Chemotherapy was 
administered according to International Pediatric Oncology Society LGG trial protocols with 
12- (LGG1, 1997-2004)(11) or 18-months (LGG2, 2005-2010)(22) first-line carboplatin and 
vincristine, and second-line cyclophosphamide, cisplatin, thioguanine, procarbazine, 
lomustine, temozolamide and/ or actinomycin-D. LGG1 was a non-randomized registry study 
testing chemotherapy as a means of avoiding or delaying radiotherapy in children <5 years 
of age, whilst LGG2, also non-randomized, extended this aim to children <8 years, reserving 
radiotherapy only for those ≥8 years of age. Prior to 1997, OP/HSGs were primarily treated 
by surgical resection with/ without radiotherapy. Patients were therefore stratified by 
treatment eras on this basis. 
Primary outcomes 
These were OS, PFS and endocrine event-free survival (EEFS), with time-to-event 
endpoints defined as death from all causes, first progression (according to international 
criteria)(23) or first hypothalamo-pituitary endocrine event respectively. 
 
Secondary outcomes 
These were the event-free survival for each hypothalamo-pituitary axis as assessed by 
departmental clinical and biochemical criteria (Supplemental Table 2): GH deficiency (GHD), 
central precocious puberty (CPP: in boys <9 years and girls <8 years at diagnosis), 
gonadotropin deficiency (GnD: in boys >14 and girls >13 years at last follow-up), ACTH 
deficiency (ACTHD), TSH deficiency (TSHD), hyperprolactinemia and PPD (central diabetes 
insipidus (CDI), syndrome of inappropriate antidiuretic hormone secretion (SIADH) or 
cerebral salt-wasting (CSW)) as well as obesity, insulin insensitivity or type 2 diabetes 
mellitus. The total number of hypothalamo-pituitary deficits at last follow-up was termed the 
endocrine morbidity score (EMS).(24). The requirement for supported or special educational 
needs schooling and blind or partial sightedness registration as per Department of Health 
England criteria(25) were surrogates for neurocognitive and visual outcomes respectively. 
More detailed analysis of visual and cognitive data is beyond the scope of this paper and will 
be published elsewhere. 
 
Statistical analysis 
Non-parametric data were summarized as medians and ranges. Categorical variables were 
compared using the χ2-test and the χ2-test for trend, whilst continuous variables were 
compared using the Kruskal-Wallis one-way analysis of variance. Kaplan-Meier survival 
curves were censored at last follow-up or death for all outcomes. Hazard ratios (HRs) with 
95% confidence intervals (CIs) were estimated by univariate and multivariate Cox 
proportional hazards regression, with the latter generated by forward stepwise selection 
(inclusion criterion p<0.05, exclusion criterion p>0.10). Predictors entered were age, sex, 
ethnicity, NF-1 status, MDC stage, tumor grade, presence of symptoms, diencephalic 
syndrome, hypothalamic involvement, leptomeningeal metastases and hydrocephalus at 
diagnosis, primary and final treatment modalities, number of progressions and surgeries, 
and treatment era. For PFS, the number of progressions, surgeries and final treatment 
modalities were excluded from analyses. Cross-sectional correlations with EMS and neuro-
ophthalmic outcomes were examined by linear and logistic regression respectively, using the 
same forward stepwise selection criteria to estimate regression coefficients β and odds 
ratios (ORs) with 95% CIs. Analyses were performed with IBM SPSS® version 21 (IBM 
Corporation, New York) with significance set at p<0.05. 
 
Ethical approval 
The GOSH Research & Development department approved this study as a case note review 
in March 2011. 
 
Results 
Patient recruitment (Table 1) 
166 of 203 registered OP/HSG patients were eligible for analysis. The following patients 
were excluded: six for inappropriate histology (two meningiomas, one grade III astrocytoma, 
one Langerhans cell histiocytosis, one glioependymal cyst, and one Alexander disease), two 
for location outside the optic pathway or suprasellar midline (one right lateral ventricle, and 
one right temporal lobe), 14 for having had their treatment and/ or follow-up in other centers, 
14 for whom no records could be located, and one for loss to follow-up. 16 of 166 eligible 
patients had no ethnicity recorded leaving 150 datasets for multivariate analyses. Two 
patients had LGGs arising post-chemotherapy for acute lymphoblastic leukemia. Tumor 
histology was only available for 63 patients (38.0%), therefore tumor grade was excluded 
from all multivariate models and only included in post hoc subcohort analyses of patients 
with histological verification. 
 
Median ages at diagnosis and follow-up were 4.9 (0.2-15.4) and 15.5 (2.4-37.4) years 
respectively, with a median follow-up of 8.3 (0.04-26.8) years. Median symptom duration 
prior to diagnosis (n=134) was 135 (1-1825) days, being longer in posterior tumors (MDC 3/4 
vs. 1: 210 (21-1460) vs. 90 (30-1460) days, p<0.05) and those without hypothalamic 
involvement (non-hypothalamic vs. hypothalamic: 150 (1-1825) vs. 90 (1-1460) days, 
p<0.01), but not in non-white patients or those presenting with endocrinopathies (p=NS).  
 
The use of surgery and radiotherapy declined significantly over successive treatment eras in 
favor of chemotherapy (1980-1996 vs. 2005-2010: surgical resections 47.7% vs. 21.6%, 
radiotherapy 53.8% vs. 29.4%, chemotherapy 23.1% vs. 49.0%; p<0.01). The age at first 
radiotherapy exposure also increased with time (median age 1980-1996 vs. 2005-2010: 6.7 
(0.6-15.9) vs. 10.2 (4.3-15.7) years; p<0.01). The proportions of non-white and symptomatic 
patients respectively increased (1980-1996 vs. 2005-2010: 10.8% vs. 47.1%; p<0.001) and 
decreased (1980-1996 vs. 2005-2010: 90.8% vs. 76.5%; p<0.05) with time, in keeping with 
service expansion and increased neuroimaging. No other independent variable followed this 
trend, nor were there differences in the proportion of patients undergoing biochemical 
endocrine testing (1980-1996 75.4%, 1997-2004 74.0%, 2005-2010 82.4%; p=NS) over 
time. 
 
Primary outcomes (Figure 1a, Tables 2-3) 
Survival for all primary outcomes plateaued by 20 years, with actuarial OS, PFS and EEFS 
being 81.0%, 47.2% and 20.8% respectively. Endocrine events occurred early with EEFS 
falling much more steeply than PFS and OS (p<0.001).  
 
OS  
13 (7.8%) patients died at a median of 8.2 (0.8-16.9) years from disease progression (nine), 
acute hydrocephalus (two), acute intratumoral hemorrhage (one) or a second primary cancer 
(one atypical teratoid rhabdoid tumor arising post-chemotherapy). Notably six (46%) had 
severe PPD (three CSW, two CDI, one SIADH) at the time of death. The only independent 
risk factor for mortality was age <1 year at diagnosis (Figure 1b, p<0.01). Subcohort analysis 
of biopsied tumors showed that non-white ethnicity independently reduced OS (HR 10.76 
(1.12-103.78), p<0.05).  
 
PFS (Figures 1c-e) 
67 (40.4%) of OP/HSGs progressed at a median 2.1 (0.1-11.7) years from diagnosis; in 
32.8% this was multiple (one progressing six times), whilst one underwent 27 operations for 
progression or hydrocephalus. Age <1 year (p<0.01) and hypothalamic involvement (p<0.01) 
were independent risk factors for progression, whilst patients with diencephalic syndrome 
(p<0.001) or hypothalamic involvement (p=0.001) were more likely to progress multiple 
times (Supplemental Table 3). In the biopsied subcohort, primary chemotherapy was 
independently associated with an increased risk of progression (HR 2.05 (1.05-3.98), 
p<0.05), whilst primary resection was conversely associated with a reduced risk (HR 0.37 
(0.18-0.73), p<0.01). Neither metastatic disease, tumor grade, treatment modalities nor 
treatment era affected OS or PFS. GH supplementation was not independently associated 
with PFS when included as part of a post-hoc multivariate model (data not shown). 
 
EEFS (Figures 2b-e) 
109 (65.7%) patients experienced their first endocrine event at a median of 0.8 (0.0-14.2) 
years from diagnosis. However, one patient with an anterior tumor (MDC stage 1) developed 
isolated GHD 14.2 years post-diagnosis after chemotherapy alone. Hypothalamic 
involvement was a stronger independent predictor of reduced EEFS (p<0.001) than primary 
radiotherapy (p<0.05). Subcohort analysis of biopsied tumors did not show any differences. 
The trend for reduced EEFS in the lattermost treatment era suggested by Kaplan-Meier 
analysis (Figure 2e) was not confirmed in the multivariate model. 
 
Secondary outcomes 
EMS (Figure 2a, Tables 2-4) 
Endocrinopathy was unusual at diagnosis with gonadotropin dysfunction being commonest  
(11.4% CPP; 14.3% GnD). At last follow-up, 54.8% had at least one endocrinopathy (median 
EMS 1 (0-6)) with a clear hierarchical evolution. GHD occurred earliest and most frequently 
(40.3%) followed by CPP (26.0%), GnD (20.4%), TSHD (13.3%), ACTHD (13.3%) and CDI 
(4.2%). 11 (6.6%) had panhypopituitarism (four with CDI). 
 
Treatment era was therefore a significant confounder in cross-sectional analysis for EMS 
(β=-0.38, 95% CI -0.63--0.13) and excluded from the multivariate model. Radiotherapy 
exposure (p<0.001) was a stronger predictor than diencephalic syndrome (p<0.01) of final 
EMS, which also increased with the number of surgical interventions (p<0.01) and 
decreased with female sex (p<0.05).  
 
Specific endocrine event-free survival (Table 4) 
Multivariate analyses of individual endocrinopathies revealed that hypothalamic involvement 
or the presence of diencephalic syndrome were more predictive of most endocrine deficits 
(CPP, GnD, ACTHD, TSHD, PPD) than treatment-related factors such as radiotherapy 
exposure. Radiotherapy was the strongest risk factor for GHD (p<0.001), but did not 
independently predict CPP, TSHD or PPD. GHD significantly increased in later treatment 
eras (p<0.01), whilst PPD significantly decreased between 1997-2004 (p<0.05).  The 
protective effect of female sex on EMS was CPP- (p=0.03) and ACTHD-specific (p=0.009).  
 
One GHD, two ACTHD (likely secondary to dexamethasone suppression) and ten PPD 
cases were reversible. Notably, CPP could evolve to future GnD (37.5% of CPP vs. 14.6% 
of non-CPP patients subsequently developed GnD, p=0.048; 50.0% of GnD vs. 19.6% of 
non-GnD patients had previous CPP, p=0.02). Most hyperprolactinemia was transient and 
only one galactorrheic patient (prolactin >1000 mU/l) required cabergoline. On multivariate 
analysis, surgery was the only treatment-related factor predicting PPD (p<0.05), the risk 
increasing with repeated operations (p<0.05, supplemental Table 4). Only three of 22 
patients had PPD at diagnosis (two with hypothalamic tumors, one with a third ventricle 
tumor), the remainder having all undergone surgery prior to its onset; in 11/19 (57.9%) this 
was a biopsy or decompression procedure alone. 
 
Visual and neurocognitive outcomes (Supplemental Tables 5 & 6) 
At last follow-up, 21.1% of patients were registered blind or partially sighted, 36.1% had 
required supported schooling, and 15.7% had attended a special needs school. Poor visual 
and educational outcomes were strongly predicted by posteriorly extensive (MDC stage 3/4), 
multiply progressive, or metastatic tumors. Primary resection was associated with reduced 
special school attendance, although conversely, if part of the final treatment strategy, 
resections were associated with blind registration and special school attendance. Girls and 
patients treated in latter treatment eras were less likely to require supported or special needs 
schooling. Radiotherapy did not independently predict visual or cognitive dysfunction whilst a 
higher EMS predicted a higher likelihood of requiring supported (p=0.001) or special needs 
schooling (p=0.004, data not shown).  
 
Neurological morbidity was otherwise rare; three patients developed moya-moya disease (all 
post-radiotherapy, one with NF-1) and two patients suffered strokes after surgery and 
radiotherapy, one of whom also had chemotherapy. 
 
Discussion 
The high actuarial 20-year OS we report for OP/HSGs in this study is comparable to 
published literature.(9-11) Thus, minimizing future endocrine, visual and cognitive morbidity 
remains an important therapeutic goal in managing these tumors. Whilst endocrine 
dysfunction appears easily treatable, combined ACTHD and PPD can be life-
threatening(26), GnD impairs future fertility, and obesity, with its long-term cardiovascular 
and metabolic sequelae, is in itself life-limiting. The lower concurrent PFS rates we and 
others have demonstrated (47-51%)(9, 10) additionally indicate that the optimal treatment 
strategy for these benign lesions remains elusive; whilst the absence of longitudinal 
neuroendocrine morbidity data limits our understanding of their etiology and evolution. 
Armstrong et al.’s single-center study is the only other longitudinal analysis of long-term 
LGG outcomes, but this was not OP/HSG-specific and thus biased by the larger proportion 
of more peripheral and easily resectable tumors.(9)  
 
Our study uniquely examines the longitudinal evolution and predictors of neuroendocrine 
dysfunction over three decades in the largest OP/HSG-specific cohort reported to date. Our 
predictors of reduced OS and PFS (age <1 year and hypothalamic involvement) agree with 
previous reports, with hypothalamic tumors and patients with diencephalic syndrome 
progressing repeatedly.(10-13) Unlike LGGs elsewhere, OP/HSG-specific survival is not 
independently predicted by NF-1 status, tumor grade, or metastases; their effect probably 
negated by the intrinsic progressive nature of tumors in this location.(8, 11, 13, 27) Our 
study also supports the safety of GH supplementation in these cases with tumor progression 
rates being unaffected as previously reported.(28, 29) 
 
Although tumor location, radiotherapy and surgery have all been implicated in OP/HSG-
related endocrinopathy, these univariate cross-sectional studies fail to separate tumor- from 
treatment-related effects.(8, 17, 18) Contrastingly, our multivariate longitudinal analysis 
confirms our hypothesis that both tumor location and treatment modalities influence long-
term neuroendocrine morbidity. By introducing the concept of EEFS, we show that whilst 
tumor location predicts the tempo of endocrinopathy, radiotherapy compounds its density, 
particularly GHD. The strong association between GHD and radiotherapy explains 
Armstrong et al.’s findings that complete resection, in a largely peripheral LGG cohort, 
reduces GHD by obviating the need for adjuvant irradiation.(9) Given the pre-existing 
hypothalamic disruption and the propensity for multiple disease progressions, it is 
unsurprising that infants with diencephalic syndrome were also more likely to develop 
multiple endocrinopathies. 
 
The hierarchical evolution in hypothalamo-pituitary dysfunction observed echoes that 
previously described in OP/HSGs, craniopharyngiomas and other suprasellar tumors.(15, 
27, 30, 31) Its pathogenesis is poorly understood but is thought to reflect a differential 
radiosensitivity(31)  and/ or the embryonal transcriptional cascade regulating anterior 
pituitary development.(32) However, apart from GHD and insulin resistance, 
endocrinopathies were predicted more by hypothalamic involvement than treatment, 
supporting the idea that tumor mass causes primary hypothalamo-pituitary injury, and 
progression may thus cause further dysfunction.  
 
We could identify no treatment modality as an independent risk factor for PPD, likely due to 
its rarity. However, all affected patients without PPD at diagnosis developed this exclusively 
in the immediate post-operative period, with >50% reported as having only had biopsies or 
decompression procedures without significant resection. Its association with 46% of deaths 
in our cohort highlights the need for careful risk-benefit analysis of any surgery, even in the 
absence of major tumor excision. 
 
CNS tumor-associated obesity is etiologically multifactorial.(33) We demonstrate a 
previously unreported high prevalence in OP/HSGs (50% at 20 years), which together with 
insulin insensitivity is increased by radiotherapy. Although none of our patients developed 
frank type 2 diabetes, this may yet occur with longer follow-up (>30 years) and incur 
consequential cardiovascular risks. Patients with posteriorly extensive, multiply progressive, 
metastatic or surgically resected tumors were most likely to experience visual loss or require 
educational support. The association between EMS and cognitive morbidity suggests that 
both are markers of increased hypothalamo-pituitary injury. 
 
Therefore, in aiming to improve long-term outcomes for OP/HSGs, there is a precarious 
balance between preventing disease progression and minimizing long-term treatment 
toxicity. The suggested reduction in EEFS (particularly GHD) we observed with successive 
treatment eras is concerning given the lack of a corresponding improvement in survival. Due 
to concerns regarding early cranial irradiation exposure and cognitive dysfunction, 
chemotherapy was increasingly incorporated into treatment regimens to delay or avoid 
radiotherapy.(34) Although radiotherapy has long been assumed to cause greater 
neuroendocrine toxicity, in our cohort it was only associated with GHD, GnD and ACTHD, 
and not with CPP, TSHD, PPD, obesity, insulin resistance, visual or cognitive dysfunction, 
the latter of which can occur even in the absence of radiotherapy.(35) Modern, focal 
radiotherapeutic techniques limiting exposure of healthy brain tissue have demonstrated less 
long-term neuroendocrine morbidity(36).  
 
In our subcohort of biopsied patients, primary chemotherapy was associated with an 
increased likelihood of progression, confirming previous literature on chemotherapy’s failure 
to stabilize disease and prevent visual deterioration.(3, 10, 11) Primary resection reduced 
progression rates as previously reported.(9-11) However, given the perioperative risk of PPD 
even with procedures not aimed at tumor resection and its possible association with 
mortality, attempts at resecting OP/HSGs must be carefully considered.  
 
We thus postulate that failure of a first-line chemotherapeutic strategy in preventing OP/HSG 
progression necessitates multiple salvage surgical or radiotherapeutic interventions which 
can, together with tumor growth, compound neuroendocrine morbidity. Two other lines of 
evidence support this; firstly, the reduction in EEFS over time was largely GHD-specific and 
strongly predicted by radiotherapy, despite its less frequent use; and secondly, the 
association between multiple surgeries and a worse EMS suggests failure to stabilize 
disease necessitating repeated treatments. Furthermore, the improved cognitive outcomes 
seen after primary resection contrast with the increased visual and cognitive morbidity seen 
when surgery is part of the final treatment strategy, likely reflecting the ease of resectability – 
and hence cure or stabilization – of tumors selected for primary resection. 
 
The protective effect of female sex on EMS and cognition are new unexplained findings 
requiring further study. The only prior evidence for sexually dimorphic neuroendocrine 
outcomes is converse– female cranially irradiated medulloblastoma and leukemia survivors 
experience a greater radiation-induced cognitive decline.(37, 38) Similarly, the association 
between non-white ethnicity and a reduced OS has never been described, possibly due to a 
lack of ethnicity data in multicenter international trials. It is unlikely to be due to differences in 
healthcare access given the similar times to diagnosis between groups, and may have an as 
yet undefined genetic basis coding for more molecularly unfavorable tumors. 
 
The retrospective nature of this study limits our findings. We assumed normal endocrine 
function without clinical or biochemical evidence to the contrary which may underdiagnose 
endocrinopathies,(24) as illustrated by the late GHD diagnosis which may well have been an 
occult idiopathic GHD already present pre-treatment. The low incidence of endocrinopathies 
at diagnosis may reflect the difficulties of performing dynamic endocrine tests prior to 
oncological therapy, particularly to diagnose GHD and ACTHD. However, there was no 
change in the frequency of follow-up endocrine testing over successive eras.   We also 
omitted primary endocrine dysfunction (three with autoimmune hypothyroidism, one with 
idiopathic primary ovarian failure) from our analyses as this was unlikely to be related to 
hypothalamo-pituitary injury.  
 
Determining the degree of surgical resection achieved was difficult across treatment eras 
and between individual surgeons due to variations in the definition of terms such as 
“debulking”, “subtotal resection” and “incomplete resection”. Only seven tumors (4.2%, four 
MDC 1 and three third ventricle tumors) were completely resected. We did not assess tumor 
invasiveness beyond documenting MDC stage, grade, metastases, and hydrocephalus, as 
radiological parameters such as tumor volume, apparent diffusion coefficients or fractional 
anisotropy were impossible in the pre-MRI era.(39, 40) Although this is the largest OP/HSG-
specific longitudinal neuroendocrine morbidity study to date, our cohort size still prevented 
sub-analysis of the effect of degree of resection, radiotherapy doses and various 
chemotherapy regimens on outcomes. 
 
The third international LGG study (LGG3) is currently being designed and will, for the first 
time, collect prospective longitudinal neuroendocrine morbidity data as part of a randomized-
controlled chemotherapeutic trial. Importantly, randomization will mandate tumor biopsy, and 
our data suggests that its impact on PPD and other neuroendocrine outcomes requires 
careful study. Although radiotherapy is not being considered for randomization, this may 
need careful consideration given the precision of modern irradiation techniques, a lack of 
evidence for the superiority of chemotherapy and our observation that many of the 
neuroendocrinopathies observed are secondary to tumor location rather than irradiation 
exposure. The hierarchical, evolutionary nature of endocrine deficits over prolonged intervals 
suggests that early routine and lifelong endocrine follow-up is paramount in all these 
patients, for instance to diagnose evolving GnD even in the presence of previous pubertal 
precocity. Longer-term subfertility, type 2 diabetes and cardiovascular outcomes require 
more prolonged data collection and a paradigm shift from measuring the quantity of survival 
to prioritization of its quality, implicit in the British Neuro-oncology Society’s recent 
recommendation that OP/HSGs be managed as a chronic disease rather than a classical 
malignancy.(22) 
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Table & Figure Legends 
Table 1 Demographic, tumor- and treatment-related characteristics, and trends by 
treatment era. NF-1, neurofibromatosis type 1; MDC, modified Dodge classification; JPA, 
juvenile pilocytic astrocytoma; SEGA, subependymal giant cell astrocytoma; NOS, not 
otherwise specified. *p-values are for the χ2-test for trend or the Kruskal-Wallis one-way 
analysis of variance. 
 
Table 2 20-year overall (OS), progression-free (PFS), endocrine event-free survival 
(EEFS) and endocrine morbidity score (EMS) at last follow-up with crude hazard ratios 
(HRs, 95% confidence intervals (CI)) and unadjusted regression coefficients β respectively. 
NF-1, neurofibromatosis type 1; MDC, modified Dodge classification. *All patients with 
leptomeningeal metastases survived to last follow-up. §All patients with diencephalic 
syndrome and/ or leptomeningeal metastases progressed. #All patients aged <1 year at 
diagnosis, with diencephalic syndrome, hypothalamic involvement or leptomeningeal 
metastases experienced ≥1 endocrinopathy. 
 
Table 3 Predictors included in the multivariate Cox and linear regression models for 
overall (OS), progression-free (PFS), endocrine event-free survival (EEFS) and endocrine 
morbidity score (EMS), ranked by magnitude of hazard ratio (HR) or regression coefficient β. 
CI, confidence interval. 
 
Table 4 Prevalence at diagnosis & last follow-up, 20-year event-free survival, 
predictors included in the multivariate Cox regression model, hazard ratios (HRs) and 95% 
confidence intervals (CIs) for individual endocrine events. GHD, growth hormone deficiency; 
CPP, central precocious puberty; GnD, gonadotropin deficiency; ACTHD, 
adrenocorticotropic hormone deficiency; TSHD, thyroid stimulating hormone deficiency; 
hyperPRL, hyperprolactinemia; PPD, posterior pituitary dysfunction; CDI, central diabetes 
insipidus; SIADH, syndrome of inappropriate antidiuretic hormone secretion; CSW, cerebral 
salt-wasting syndrome. For univariate HRs see Supplemental Table 4. 
 
Figure 1 Kaplan Meier survival curves and life tables for (a) actuarial overall (OS), 
progression-free (PFS) and endocrine event-free survival (EEFS); (b) OS by age; (c-e) PFS 
by age, the presence of diencephalic syndrome (DS) and hypothalamic involvement 
respectively. 
 
Figure 2  Kaplan Meier survival curves and life tables for endocrine event-free survival 
(EEFS) by (a) individual EEFS, (b) presence of hypothalamic involvement, use of 
radiotherapy as part of the primary (c) and final (d) treatment strategies respectively, and 
treatment era (e). GHD, growth hormone deficiency; CPP, central precocious puberty; GnD, 
gonadotropin deficiency; ACTHD, adrenocorticotropic hormone deficiency; TSHD, thyroid 
stimulating hormone deficiency; DI, diabetes insipidus; RT, radiotherapy.  
 Independent variable 
n/ median 
(%/ range) 
By treatment era (%) 
p* 
1980-1996 (n=65) 1997-2004 (n=50) 2005-2010 (n=51) 
Age 
 >5 years 
 1-5 years 
 <1 year 
 
81 (48.5) 
69 (41.6) 
16 (9.6) 
 
30 (46.2) 
28 (43.1) 
7 (10.8) 
 
27 (54.0) 
19 (38.0) 
4 (8.0) 
 
24 (47.1) 
22 (43.1) 
5 (9.8) 
 
0.834 
Sex 
 Male 
 Female 
 
76 (45.8) 
90 (54.2) 
 
27 (41.5) 
38 (58.5) 
 
24 (48.0) 
26 (52.0) 
 
25 (49.0) 
26 (51.0) 
0.410 
Ethnicity (n=150) 
 White 
 Non-white 
 Unknown 
 
114 (68.7) 
36 (21.7) 
16 (9.6) 
 
43 (66.2%) 
7 (10.8%) 
15 (23.1%) 
 
44 (88.0%) 
5 (10.0%) 
1 (2.0%) 
 
27 (52.9%) 
24 (47.1) 
0 (0.0%) 
<0.001 
NF-1 status 
 Negative 
 Positive 
 
98 (59.0) 
68 (41.0) 
 
39 (60.0) 
26 (40.0) 
 
29 (58.0) 
21 (42.0) 
 
30 (58.8) 
21 (41.2) 
0.889 
Symptomatic 
 No 
 Yes 
 
27 (16.3) 
139 (83.7) 
 
6 (9.2) 
59 (90.8) 
 
9 (18.0) 
41 (82.0) 
 
12 (23.5) 
39 (76.5) 
0.037 
Diencephalic syndrome 
 No 
 Yes 
 
153 (92.2) 
13 (7.8) 
 
59 (90.8) 
6 (9.2) 
 
47 (94.0) 
3 (6.0) 
 
47 (92.2) 
4 (7.8) 
0.754 
Tumor stage 
 MDC 1 
 MDC 2 
 MDC 3/4 
 MDC other midline 
 
29 (17.5) 
76 (45.8) 
34 (20.5) 
27 (16.3) 
 
12 (18.5) 
28 (43.1) 
13 (20.0) 
12 (18.5) 
 
8 (16.0) 
23 (46.0) 
11 (22.0) 
8 (16.0) 
 
9 (17.6) 
25 (49.0) 
10 (19.6) 
7 (13.7) 
0.623 
Hypothalamic involvement 
 No 
 Yes 
 
99 (59.6) 
67 (40.4) 
 
38 (58.5) 
27 (41.5) 
 
31 (62.0) 
19 (38.0) 
 
30 (58.8) 
21 (41.2) 
0.947 
Leptomeningeal metastases 
 No 
 Yes 
 
160 (96.4) 
6 (3.6) 
 
63 (96.9) 
2 (3.1) 
 
48 (96.0) 
2 (4.0) 
 
49 (96.1) 
2 (3.9) 
0.801 
Hydrocephalus 
 No 
 Yes 
 
105 (63.3) 
61 (36.7) 
 
37 (56.9) 
28 (43.1) 
 
33 (66.0) 
17 (34.0) 
 
35 (68.6) 
16 (31.4) 
0.186 
Tumor grade 
 Grade I 
  JPA 
  SEGA 
  NOS 
 Grade II 
  Diffuse fibrillary astrocytoma 
  Pilomyxoid astrocytoma 
  NOS 
 Not biopsied/ no histology 
 
51 (30.7) 
40 (24.1) 
2 (1.2) 
9 (5.4) 
12 (7.2) 
6 (3.6) 
3 (1.8) 
3 (1.8) 
103 (62.0) 
 
21 (32.3) 
 
 
 
8 (12.3) 
 
 
 
36 (55.4) 
 
17 (34.0) 
 
 
 
2 (4.0) 
 
 
 
31 (62.0) 
 
13 (25.5) 
 
 
 
2 (3.9) 
 
 
 
36 (70.6) 
0.188 
Primary treatment strategy 
 Observation only 
 Resection only 
 Decompression without resection 
 Radiotherapy 
 Chemotherapy 
 Any surgery + radiotherapy 
 Any surgery + chemotherapy 
 
 Any primary resection 
 Any primary decompression 
 Any primary radiotherapy 
 Any primary chemotherapy 
 
58 (34.9) 
17 (10.2) 
4 (2.4) 
19 (11.4) 
20 (12.0) 
26 (15.7) 
22 (13.3) 
 
53 (31.9) 
50 (30.1) 
45 (27.1) 
42 (25.3) 
 
20 (30.8) 
13 (20.0) 
3 (4.6) 
10 (15.4) 
3 (4.6) 
12 (18.5) 
4 (6.2) 
 
26 (40.0) 
23 (35.4) 
22 (33.8) 
7 (10.8) 
 
19 (38.0) 
1 (2.0) 
1 (2.0) 
3 (6.0) 
8 (16.0) 
10 (20.0) 
8 (16 .0) 
 
16 (32.0) 
14 (28.0) 
13 (26.0) 
16 (32.0) 
 
19 (37.3) 
3 (5.9) 
0 (0.0) 
6 (11.8) 
9 (17.6) 
4 (7.8) 
10 (19.6) 
 
11 (21.6) 
13 (25.5) 
10 (19.6) 
19 (37.3) 
 
 
 
 
0.263 
 
 
 
 
0.036 
0.241 
0.086 
0.001 
Final treatment strategy 
 Observation only 
 Surgery only 
 Radiotherapy only 
 Chemotherapy only 
 Any surgery + radiotherapy 
 Any surgery + chemotherapy 
 Radiotherapy + chemotherapy 
 Any surgery + radiotherapy + chemotherapy 
 
 Any resection 
 Any decompression 
 Any radiotherapy 
 Any chemotherapy 
 
38 (22.9) 
21 (12.7) 
15 (9.0) 
20 (12.0) 
31 (18.7) 
18 (10.8) 
6 (3.6) 
17 (10.2) 
 
60 (36.1) 
67 (40.4) 
69 (41.6) 
61 (36.7) 
 
14 (21.5) 
12 (18.5) 
4 (6.2) 
2 (3.1) 
20 (30.8) 
2 (3.1) 
2 (3.1) 
9 (13.8) 
 
31 (47.7) 
32 (49.2) 
35 (53.8) 
15 (23.1) 
 
13 (26.0) 
3 (6.0) 
5 (10.0) 
7 (14.0) 
8 (16.0) 
8 (16.0) 
1 (2.0) 
5 (10.0) 
 
18 (36.0) 
19 (38.0) 
19 (38.0) 
21 (42.0) 
 
11 (21.6) 
6 (11.8) 
6 (11.8) 
11 (21.6) 
3 (5.9) 
8 (15.7) 
3 (5.9) 
3 (5.9) 
 
11 (21.6) 
16 (31.4) 
15 (29.4) 
25 (49.0) 
 
 
 
 
0.729 
 
 
 
 
 
0.004 
0.050 
0.007 
0.003 
Number of progressions 0 (0-6) 0 (0-6) 0 (0-4) 0 (0-5) 0.710 
Number of surgeries 1 (0-27) 1 (0-27) 0 (0-24) 0 (0-12) 0.043 
Table 1: Demographic, tumor- and treatment-related characteristics, and trends by treatment era. NF-1, 
neurofibromatosis type 1; MDC, modified Dodge classification; JPA, juvenile pilocytic astrocytoma; SEGA, 
subependymal giant cell astrocytoma; NOS, not otherwise specified. *p-values are for the χ2-test for trend or the 
Kruskal-Wallis one-way analysis of variance.
Independent variable OS (95% CI)   PFS (95% CI) EEFS (95% CI) EMS (95% CI) 
20-year OS  Crude HR p 20-year PFS Crude HR  p 20-year EEFS  Crude HR  p Crude β p 
Age  >5 years 
   1-5 years 
   <1 year 
88.7 (76.1-100.0) 
80.0 (60.6-99.3) 
62.9 (32.6-93.1) 
1.00 
1.05 (0.28-3.94) 
5.29 (1.32-21.22) 
 
0.945 
0.019 
53.4 (36.1-70.8) 
49.5 (34.4-64.5) 
6.7 (0.0-23.2) 
1.00 
1.17 (0.69-2.00) 
5.26 (2.66-10.42) 
 
0.566 
<0.001 
23.8 (13.2-34.5) 
25.6 (11.1-40.0) 
0.0# 
1.00 
0.64 (0.43-0.97) 
1.40 (0.78-2.53) 
 
0.034 
0.260 
-0.02 (-0.07-0.04) 0.600 
Sex   Male 
   Female 
78.8 (55.7-100.0) 
82.6 (59.4-95.8) 
1.00 
1.02 (0.34-3.03) 
 
0.978 
45.7 (27.5-63.8) 
48.4 (36.8-60.1) 
1.00 
1.37 (0.84-2.23) 
 
0.211 
26.7 (14.2-39.2) 
16.5 (5.6-27.5) 
1.00 
0.99 (0.68-1.45) 
 
0.972 
-0.11 (-0.54-0.32)   
Ethnicity (n-150) White 
   Non-white 
88.3 (79.6-96.9) 
36.5 (0.0-89.5) 
1.00 
2.43 (0.73-8.13) 
 
0.151 
46.8 (34.2-59.4) 
37.3 (15.6-59.1) 
1.00 
1.49 (0.85-2.62) 
 
0.161 
21.9 (11.7-32.0) 
10.5 (0.0-27.4) 
1.00 
1.24 (0.79-1.96) 
 
0.350 
0.01 (-0.53-0.55) 0.979 
NF-1  Negative 
   Positive 
78.5 (63.4-93.7) 
88.2 (73.6-100.0) 
1.00 
0.52 (0.14-1.90) 
 
0.520 
37.6 (24.9-50.3) 
62.8 (45.0-80.7) 
1.00 
0.43 (0.25-0.74) 
 
0.002 
13.0 (4.7-21.3) 
33.0 (15.3-50.8) 
1.00 
0.45 (0.30-0.68) 
 
<0.001 
-0.96 (-1.37--0.55) <0.001 
Symptomatic No 
   Yes 
95.7 (87.6-100.0) 
80.2 (67.3-93.1) 
1.00 
1.53 (0.20-11.96) 
 
0.686 
73.9 (56.0-91.9) 
44.0 (32.9-55.1) 
1.00 
1.97 (0.85-4.56) 
 
0.114 
10.6 (0.0-37.4) 
20.1 (11.8-28.4) 
1.00 
1.93 (1.06-3.52) 
 
0.032 
1.00 (0.44-1.56) 0.001 
Diencephalic syndrome 
   No 
   Yes 
 
80.8 (66.8-94.8) 
78.3 (50.8-100.0) 
 
1.00 
1.99 (0.44-9.04) 
 
 
0.375 
 
53.3 (42.5-64.1) 
0.0§ 
 
1.00 
4.13 (2.19-7.79) 
 
 
<0.001 
 
23.5 (14.3-32.7) 
0.0# 
 
1.00 
1.74 (0.95-3.18) 
 
 
0.073 
1.40 (0.63-2.17) <0.001 
Tumor stage MDC 1 
   MDC 2 
   MDC 3/4 
   MDC other 
   midline 
89.1 (74.2-100.0) 
82.8 (64.9-100.0) 
80.0 (55.2-100.0) 
80.4 (62.7-98.0) 
1.00 
0.81 (0.16-4.23) 
0.71 (0.10-5.07) 
1.82 (0.33-10.03) 
 
0.806 
0.735 
0.491 
68.3 (33.1-
100.0) 
48.7 (34.3-63.2) 
37.3 (13.8-60.9) 
33.6 (12.7-54.6) 
1.00 
3.64 (1.29-10.30) 
4.00 (1.34-11.97) 
4.93 (1.63-14.87) 
 
0.015 
0.013 
0.005 
54.4 (21.0-87.8) 
13.5 (2.7-24.3) 
21.7 (6.4-37.0) 
14.1 (0.0-29.2) 
1.00 
4.31 (2.05-9.08) 
3.45 (1.55-7.70) 
3.94 (1.74-8.91) 
 
<0.001 
0.002 
0.001 
0.27 (0.05-0.49) 0.019 
Hypothalamic involvement 
   No 
   Yes 
 
87.3 (76.4-98.3) 
73.1 (49.7-96.5) 
 
1.00 
1.75 (0.59-5.20) 
 
 
0.318 
 
60.3 (46.4-74.3) 
27.9 (12.5-43.3) 
 
1.00 
2.86 (1.75-4.67) 
 
 
<0.001 
 
38.6 (25.9-51.3) 
0.0# 
 
1.00 
3.03 (2.04-4.48) 
 
 
<0.001 
1.11 (0.71-1.52)) <0.001 
Leptomeningeal metastases 
   No 
   Yes 
 
80.4 (67.4-93.3) 
100.0* 
 
1.00 
0.05 (0.00-∞) 
 
 
0.630 
 
48.7 (37.8-59.5) 
0.0§ 
 
1.00 
2.09 (0.76-5.78) 
 
 
0.155 
 
22.0 (13.3-30.7) 
0.0# 
 
1.00 
0.95 (0.35-2.59) 
 
 
0.922 
1.46 (0.33-2.58) 0.012 
Hydrocephalus No 
   Yes 
87.4 (86.8-87.1) 
72.1 (47.5-96.8) 
1.00 
2.00 (0.67-5.99) 
 
0.213 
54.5 (41.0-68.0) 
35.0 (18.2-51.7) 
1.00 
1.64 (1.01-2.66) 
 
0.045 
24.6 (12.6-36.5) 
14.9 (3.7-26.2) 
1.00 
1.65 (1.13-2.42) 
 
0.010 
0.47 (0.03-0.91) 0.037 
Tumor grade (n=63) Grade I 
   Grade II 
87.0 (76.7-94.7) 
60.3 (10.6-100.0) 
1.00 
2.71 (0.44-16.56) 
 
0.280 
23.2 (6.93-39.5) 
35.9 (6.2-65.5) 
1.00 
1.02 (0.45-2.32) 
 
0.961 
10.6 (0.0-21.4) 
5.6 (0.0-20.0) 
1.00 
1.86 (0.95-3.64) 
 
0.072 
0.30 (-0.73-1.34) 0.559 
Primary treatment strategy 
   Untreated 
   Resection 
   Decompression 
   Radiotherapy 
   Chemotherapy 
 
91.9 (82.9-100.0) 
78.0 (55.6-100.0) 
68.7 (38.3-99.0) 
71.8 (47.6-95.9) 
84.7 (65.8-100.0) 
 
1.00 
0.70 (0.21-2.29) 
1.52 (0.50-4.65) 
2.04 (0.68-6.11) 
1.01 (0.28-3.67) 
 
 
0.553 
0.466 
0.201 
0.989 
 
59.3 (38.4-80.3) 
42.7 (27.9-57.4) 
33.3 (15.5-51.1) 
40.9 (21.2-60.6) 
39.9 (22.6-57.2) 
 
1.00 
1.39 (0.85-2.27) 
1.61 (0.98-2.63) 
1.05 (0.62-1.77) 
1.64 (0.97-2.76) 
 
 
0.184 
0.060 
0.865 
0.063 
 
33.3 (14.7-52.0) 
11.7 (1.0-22.5) 
9.5 (0.0-19.6) 
4.1 (0.0-10.4) 
9.1 (0.0-22.1) 
 
1.00 
1.76 (1.20-2.59) 
1.85 (1.25-2.74) 
2.99 (2.00-4.46) 
0.87 (0.56-1.33) 
 
 
0.004 
0.002 
<0.001 
0.515 
 
 
0.66 (0.21-1.11) 
0.58 (0.12-1.04) 
1.06 (0.60-1.51) 
-0.13 (-0.62-0.36) 
 
 
0.004 
0.014 
<0.001 
0.603 
Final treatment strategy 
   Untreated 
   Resection 
   Decompression 
   Radiotherapy 
   Chemotherapy 
 
100.0§ 
76.5 (57.3-95.7) 
68.1 (46.5-89.7) 
73.5 (55.0-92.0) 
75.3 (52.0-98.5) 
 
1.00 
1.06 (0.35-3.19) 
3.27 (1.00-10.66) 
2.41 (0.74-7.86) 
1.01 (0.33-3.10) 
 
 
0.923 
0.049 
0.145 
0.986 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
 
34.3 (8.2-60.4) 
11.9 (1.8-22.0) 
10.1 (1.2-19.0) 
3.0 (0.0-8.2) 
13.8 (1.0-26.7) 
 
1.00 
1.68 (1.15-2.45) 
1.75 (1.20-2.55) 
3.39 (2.28-5.04) 
0.94 (0.64-1.39) 
 
 
0.008 
0.004 
<0.001 
0.751 
 
 
0.76 (0.33-1.19) 
0.64 (0.21-1.06) 
1.37 (0.99-1.75) 
0.21 (-0.24-0.65) 
 
 
0.001 
0.004 
<0.001 
0.355 
Treatment era 1980-1996 
   1997-2004 
   2005-2010 
78.0 (63.7-92.4) 
88.7 (74.2-100.0) 
97.1 (91.5-100.0) 
1.00 
0.53 (0.14-2.00) 
0.53 (0.06-4.80) 
 
0.529 
0.534 
51.8 (38.2-65.5) 
39.8 (16.9-62.6) 
53.8 (38.2-69.5) 
1.00 
1.01 (0.57-1.78) 
1.41 (0.77-2.61) 
 
0.968 
0.269 
24.9 (12.4-37.4) 
20.5 (5.1-35.8) 
19.2 (1.4-36.9) 
1.00 
0.92 (0.59-1.45) 
1.27 (0.80-2.04) 
 
0.728 
0.316 
-0.38 (-0.63--0.13) 0.003 
Number of progressions - 1.43 (1.08-1.90) 0.012 - - - - 1.16 (1.01-1.32) 0.030 0.40 (0.22-0.58) <0.001 
Number of surgeries - 1.04 (0.96-1.14) 0.327 - - - - 1.04 (1.01-1.08) 0.026 0.14 (0.08-0.19) <0.001 
Table 2: 20-year overall (OS), progression-free (PFS), endocrine event-free survival (EEFS) and endocrine morbidity score (EMS) at last follow-
up with crude hazard ratios (HRs, 95% confidence intervals (CI)) and unadjusted regression coefficients β respectively. NF-1, neurofibromatosis 
type 1; MDC, modified Dodge classification. *All patients with leptomeningeal metastases survived to last follow-up. §All patients with 
diencephalic syndrome and/ or leptomeningeal metastases progressed. #All patients aged <1 year at diagnosis, with diencephalic syndrome, 
hypothalamic involvement or leptomeningeal metastases experienced ≥1 endocrinopathy.
Outcome Independent predictors Adjusted HR/ β (95% CI) p 
OS Age (vs. >5 years) 
 1-5 years 
 <1 year 
Primary radiotherapy 
Non-white ethnicity 
 
 
2.10 (0.46-9.66) 
17.38 (2.81-107.29) 
3.88 (0.98-15.42) 
3.42 (0.97-12.02) 
 
 
0.341 
0.002 
0.054 
0.055 
PFS Age (vs. >5 years) 
 1-5 years 
 <1 year 
Hypothalamic involvement 
 
 
1.23 (0.71-2.13) 
3.11 (1.50-6.48) 
2.33 (1.35-4.03) 
 
0.467 
0.002 
0.003 
EEFS Hypothalamic involvement 
Primary radiotherapy 
Any radiotherapy 
 
2.20 (1.41-3.42) 
1.98 (1.16-3.39) 
1.67 (0.95-2.94) 
<0.001 
0.013 
0.074 
EMS Any radiotherapy 
Diencephalic syndrome 
No. of surgeries 
Female sex 
 
1.27 (0.88-1.65) 
0.93 (0.23-1.63) 
0.08 (0.03-0.13) 
-0.41 (-0.78--0.03) 
<0.001 
0.009 
0.004 
0.034 
Table 3: Predictors included in the multivariate Cox and linear regression models for overall 
(OS), progression-free (PFS), endocrine event-free survival (EEFS) and endocrine morbidity 
score (EMS), ranked by magnitude of hazard ratio (HR) or regression coefficient β. CI, 
confidence interval.
Endocrine event n (%) 20-year event-free 
survival (95% CI) 
Independent predictors Adjusted HR (95% 
CI) 
p 
At diagnosis At last 
follow-up 
GHD 1 (0.6) 
 
67 (40.3) 39.2 (27.2-51.2) Any radiotherapy 
Treatment era (vs. 1980-
1996) 
 1997-2004 
 2005-2010 
Primary radiotherapy 
No. of surgeries 
 
5.76 (2.93-11.32) 
 
 
0.89 (0.50-1.58) 
2.48 (1.29-4.79) 
2.48 (1.36-4.52) 
1.09 (1.04-1.14) 
<0.001 
 
 
0.682 
0.007 
0.003 
<0.001 
CPP 14/123 (11.4) 
 
32/123 (26.0) 69.7 (60.8-78.6) Hypothalamic involvement 
Female sex 
Any chemotherapy 
 
4.42 (1.97-9.92) 
0.43 (0.21-0.90) 
0.42 (0.20-0.90) 
<0.001 
0.024 
0.026 
GnD 1/7 (14.3) 
 
21/103 (20.4) 58.4 (39.4-77.4) Hypothalamic involvement 
Primary radiotherapy 
 
5.09 (1.95-13.31) 
3.27 (1.35-7.94) 
0.001 
0.009 
ACTHD 1 (0.6) 
 
22 (13.3) 75.6 (65.2-86.0) Diencephalic syndrome 
Primary radiotherapy 
Female sex 
Any chemotherapy 
 
15.72 (4.38-56.39) 
5.16 (2.12-12.57) 
0.30 (0.12-0.74) 
0.30 (0.10-0.92) 
<0.001 
<0.001 
0.009 
0.035 
TSHD 2 (1.2) 
 
22 (13.3) 75.3 (64.6-86.0) Hypothalamic involvement 7.18 (2.41-21.38) <0.001 
HyperPRL 5 (3.0) 
 
5 (3.0) 78.1 (64.8-91.4) - - - 
PPD 4 (2.4) 
 1 CDI 
 2 SIADH 
 1 CSW 
 
12 (7.2) 
 7 CDI 
 2 SIADH 
 3 CSW 
 
79.2 (69.8-88.7) 
 86.1 (71.6-100.0) 
 86.8 (79.0-94.6) 
 91.4 (84.4-98.5) 
Hypothalamic involvement 
Any resection 
Treatment era (vs. 1990-
1996) 
 1997-2004 
 2005-2010 
5.82 (1.64-20.67) 
4.61 (1.39-15.34) 
 
 
0.19 (0.04-0.87) 
1.25 (0.38-4.08) 
0.006 
0.013 
 
 
0.032 
0.716 
 
Obesity 23 (13.9) 
 
54 (32.5) 50.2 (35.4-65.1) - - - 
Insulin resistance 0 (0.0) 
 
16 (9.6) 73.1 (55.9-90.3) Primary decompression 
Primary radiotherapy 
 
3.96 (1.43-10.93) 
3.91 (1.42-10.80) 
0.008 
0.009 
Table 4: Prevalence at diagnosis & last follow-up, 20-year event-free survival, predictors 
included in the multivariate Cox regression model, hazard ratios (HRs) and 95% confidence 
intervals (CIs) for individual endocrine events. GHD, growth hormone deficiency; CPP, 
central precocious puberty; GnD, gonadotropin deficiency; ACTHD, adrenocorticotropic 
hormone deficiency; TSHD, thyroid stimulating hormone deficiency; hyperPRL, 
hyperprolactinemia; PPD, posterior pituitary dysfunction; CDI, central diabetes insipidus; 
SIADH, syndrome of inappropriate antidiuretic hormone secretion; CSW, cerebral salt-
wasting syndrome. For univariate HRs see Supplemental Table 4.
 
Figure 1: Kaplan Meier survival curves and life tables for (a) actuarial overall (OS), 
progression-free (PFS) and endocrine event-free survival (EEFS); (b) OS by age; (c-e) PFS 
by age, the presence of diencephalic syndrome (DS) and hypothalamic involvement 
respectively.
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Figure 2: Kaplan Meier survival curves and life tables for endocrine event-free survival 
(EEFS) by (a) individual EEFS, (b) presence of hypothalamic involvement, use of 
radiotherapy as part of the primary (c) and final (d) treatment strategies respectively, and 
treatment era (e). GHD, growth hormone deficiency; CPP, central precocious puberty; GnD, 
gonadotropin deficiency; ACTHD, adrenocorticotropic hormone deficiency; TSHD, thyroid 
stimulating hormone deficiency; DI, diabetes insipidus; RT, radiotherapy. 
 
